A new treatment for Alzheimer’s disease, lecanemab, was approved today by the FDA. It has been shown to slow disease progression for early-stage patients. The presence of beta amyloid must be confirmed before treatment. https://t.co/pNvYcwBCSD #NuclearMedicine#PETscan#Alzheimer
So finally, as a proof of concept @enthym showed that a model trained on simulated can be applied to clinical data.
Again, visual image quality improved (see images) and reader confidence increased, too.
However, a limitation is that we only had 10 patients’ data. 7/8
Those simulated #FCD lesions then had more favourable stats (better contrast) and were also twice as likely to be detected by human raters (75% vs 38%). Great!
But these were all simulated data -so what about clinically acquired data? 6/8
So far, so good, but what does this do for lesion detectability?
To find out, we created another (!) 120 phantoms with lesions designed to look like #FCD (focal cortical dysplasia), see the example … 5/8
Those 2100 standard-quality PETs were used to learn the mapping back to the ground-truth phantoms using #AI - a residual neuronal network, #ResNet.
Once you have this mapping, you can create enhanced “ #superresolution ” PET from standard PET… 3/8
We created a large database of simulated #PET data using a high-quality Monte-Carlo PET simulator. With digital brain phantoms from T1w #MRI as “ground-truth phantom” inputs, we created 2100 simulated standard quality PETs (yes, lots of number crunching!)
2/8
Autopsy Validation of the Diagnostic Accuracy of 123I-MIBG Myocardial Scintigraphy for Lewy Body Disease https://t.co/oplt7Mhl03
@GreenJournal@Enthym@So_Dautricourt